Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Interest & Investment Income (2023 - 2025)

Aclaris Therapeutics has reported Interest & Investment Income over the past 3 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $1.6 million for Q4 2025, down 22.3% from a year ago — trailing twelve months through Dec 2025 was $7.6 million (down 3.96% YoY), and the annual figure for FY2025 was $7.6 million, down 3.97%.
  • Interest & Investment Income for Q4 2025 was $1.6 million at Aclaris Therapeutics, down from $1.8 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for ACRS hit a ceiling of $2.3 million in Q3 2023 and a floor of $1.6 million in Q4 2025.
  • Median Interest & Investment Income over the past 3 years was $2.0 million (2024), compared with a mean of $2.0 million.
  • Peak annual rise in Interest & Investment Income hit 8.84% in 2025, while the deepest fall reached 22.3% in 2025.
  • Aclaris Therapeutics' Interest & Investment Income stood at $2.2 million in 2023, then dropped by 3.93% to $2.1 million in 2024, then dropped by 22.3% to $1.6 million in 2025.
  • The last three reported values for Interest & Investment Income were $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.